Anti-nectin-4 Antibody-drug Conjugate MK-3120 clinical trials
Also written MK-3120 and SKB410.
How each study uses Anti-nectin-4 Antibody-drug Conjugate MK-3120 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-nectin-4 Antibody-drug Conjugate MK-3120 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Merck Sharp & Dohme LLC (4) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-nectin-4 Antibody-drug Conjugate MK-3120.
- Jul 2027A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)Phase 1/2 · Merck Sharp & Dohme LLC
Studies
Open first, then newest update. How each study uses Anti-nectin-4 Antibody-drug Conjugate MK-3120 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06818643Written as MK-3120
- A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07222488Written as MK-3120
- KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07232602Written as MK-3120
- A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT05562830Written as MK-3120
- SKB410 for Injection in Solid TumorsCompletedPhase 1Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT05906537Written as SKB410 for injection